RMI1 inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of RMI1, a key component of the Bloom syndrome complex, also known as the BLM-Topo IIIα-RMI1-RMI2 complex. This protein complex plays a crucial role in maintaining genome stability by regulating DNA repair and recombination processes, particularly during homologous recombination and the resolution of DNA double-strand breaks. RMI1 functions as a scaffold protein, stabilizing the interactions between other members of the complex, such as the RecQ helicase BLM and topoisomerase IIIα. It is involved in dissolving recombination intermediates, ensuring proper DNA repair and preventing harmful chromosomal rearrangements. Inhibition of RMI1 disrupts its interaction with other proteins in this complex, potentially leading to impaired DNA repair mechanisms and altered genome stability.
The development of RMI1 inhibitors requires an understanding of the protein's structural features, particularly the domains that mediate its interactions with BLM and topoisomerase IIIα. These inhibitors typically target specific binding interfaces or regions of RMI1 that are essential for maintaining the integrity of the BLM complex. By blocking these interactions, RMI1 inhibitors prevent the proper assembly or function of the complex, affecting its ability to resolve DNA structures and maintain genomic stability. Structural biology techniques such as X-ray crystallography and molecular docking are often used to identify the key domains involved in these protein-protein interactions and to design inhibitors with high specificity for RMI1. Achieving specificity is critical, as many other proteins are involved in DNA repair pathways, and off-target inhibition could have unintended effects on other DNA repair processes. RMI1 inhibitors serve as valuable tools for studying the molecular mechanisms underlying genome maintenance and for exploring the intricate interactions between proteins involved in DNA recombination and repair.
Items 1 to 10 of 14 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A could downregulate RMI1 expression by modifying chromatin accessibility, leading to a condensed structure that is less amenable to transcription. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This chemical may reduce RMI1 levels by demethylating the RMI1 gene promoter, thereby hindering the binding of transcriptional activators required for RMI1 transcription. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D has the potential to decrease RMI1 mRNA levels by intercalating into DNA, which blocks the elongation phase of RNA synthesis by RNA polymerase. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Mithramycin A could suppress RMI1 expression by binding to DNA sequences upstream of the RMI1 coding region, obstructing the assembly of the transcriptional machinery. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
Doxorubicin may downregulate RMI1 by causing DNA damage and activating checkpoint pathways that repress the transcription of DNA repair genes, including RMI1. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine could reduce RMI1 expression by interfering with DNA replication and repair mechanisms, leading to a decrease in RMI1 transcription as a secondary effect. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin may inhibit RMI1 expression by stabilizing the DNA-topoisomerase I complex, causing DNA damage and triggering a cascade that downregulates DNA repair genes. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide could lead to a reduction in RMI1 expression by causing double-stranded DNA breaks and activating a DNA damage response that could include repression of RMI1. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $275.00 $474.00 $1639.00 $2497.00 $5344.00 | 4 | |
Rocaglamide potentially could decrease the production of RMI1 by inhibiting general protein translation machinery, thereby reducing RMI1 protein levels indirectly. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide has the potential to suppress RMI1 expression by inhibiting RNA polymerase II, leading to a broad decrease in gene transcription, including the gene encoding RMI1. | ||||||